Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jules Quartly

Advertisement
Set Alert for Articles By Jules Quartly

Latest From Jules Quartly

China Biotech Innovation Reaching Tipping Point?

A rapidly reforming policy and regulatory environment and a growing culture of innovation are encouraging capital and talent to pour into China, making it a question of when, rather than if, the payoffs will come for both consumers and investors.

China Financing

Mixed Views On Hong Kong Market's Role Despite IPOs Lining Up

The first IPOs to get away under Hong Kong's new relaxed rules for the listing of pre-revenue bioventures have seen mixed performances so far, and observers also have varying views on the likely success of the initiative, although the territory's stock exchange remains bullish as more companies line up to float. 
Hong Kong Financing

A Safe Harbor For Biotechs? Ascletis, BeiGene Mark Early Wins For HK Exchange

The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.

Hong Kong Commercial

New Rules Could Means IP Loss For Firms Doing R&D In China

Multinationals and M&A deals could be adversely affected by new measures in China that could delay or even block the export of intellectual property out of the country.

China Policy

Hong Kong Ushers in 'New Era' For Bioventures As Listing Rules Eased

The introduction of new listing rules in Hong Kong makes it easier for biotech companies to go public and provides incentives for both China-based and international companies to float there rather than in New York or elsewhere, although some concerns linger.

 

Hong Kong Commercial

Hong Kong Leveraging Home Court Advantage For Chinese Biotechs

The biggest shakeup of the Hong Kong Stock Exchange for three decades could see biotech businesses and innovators turn from West to East when seeking listings, as shown by plans being made by two prominent Chinese bioventures.

China Hong Kong
See All
Advertisement
UsernamePublicRestriction

Register